Duke-NUS scientists identify 2 proteins that contribute to lung scarring

Key Concepts

Pulmonary fibrosis, lung scarring, breathing difficulty, aging population, protein inhibition, disease progression, tissue injury, inflammation, fibroblast transformation, collagen secretion, COVID-19, lifestyle factors, smoking, mouse model, immune cells (macrophages), preclinical stage, clinical trials.

Pulmonary Fibrosis: An Overview

• Definition: Pulmonary fibrosis is a condition characterized by scarring of the lungs, leading to breathing difficulties.
• Symptoms: Shortness of breath, dry cough, and fatigue are common symptoms. Patients often feel "out of breath."
• Impact on Quality of Life: Pulmonary fibrosis can significantly affect daily activities such as walking and performing simple chores.
• Irreversibility: Fibrosis is generally not reversible. Current treatments focus on slowing down its progression.

Causes and Risk Factors

• Tissue Injury: Lung injury due to chemical exposure, pollution, or viral infections (like COVID-19) can trigger fibrosis.
• Inflammation: Injury leads to inflammation, which in turn causes a fibrotic response.
• Fibroblast Transformation: Inflammatory signals cause cells to transform into myofibroblasts, which secrete collagen and extracellular matrix.
• Collagen Accumulation: Excessive collagen deposition stiffens the lung tissue, impairing its ability to expand and contract.
• Aging Population: The incidence of pulmonary fibrosis is rising as the population ages.
• COVID-19: Infection with COVID-19 can increase the risk of developing pulmonary fibrosis. A study indicated that up to 45% of individuals infected with COVID-19 might develop lung fibrosis.
• Lifestyle Factors: While diet isn't directly linked to acute lung fibrosis, unhealthy lifestyles can contribute to chronic conditions. A Singapore-based study showed that 50% of individuals develop chronic conditions by age 45-50.
• Smoking and Vaping: These habits are associated with an increased risk of pulmonary fibrosis.

Duke-NUS Study: Protein Inhibition

• Mouse Model: Researchers used a mouse model to study pulmonary fibrosis.
• Key Proteins: The study focused on two proteins active in immune cells like macrophages.
• Mechanism: Activation of these proteins affects fibroblast transformation, leading to myofibroblast formation and fibrosis.
• Findings:
  • Inhibiting these proteins in the mouse model reduced fibrosis.
  • Excessive expression of these proteins exacerbated fibrosis.
• Potential Treatment Strategy: Balancing the expression of these proteins could be a therapeutic approach to control fibrosis.

Treatment Prospects and Timeline

• Early Stage Research: The research is currently in the discovery and preclinical stages.
• Timeline: It typically takes 10-15 years to translate a discovery into a viable treatment.
• Existing Inhibitors: Inhibitors targeting these two proteins are already in Phase 3 clinical trials for other conditions (specific cancers in the United States).
• Repurposing Potential: These existing inhibitors could potentially be repurposed for pulmonary fibrosis treatment.

Notable Quotes

• Indra Kumar Singh: "So people suffering from pulmonary fibrosis, they have difficulty in breathing because the long as injured and fiber optic and they they can feel like no U.S. out of breath."
• Indra Kumar Singh: "The cause of fibrosis is like any tissue injury been the longest injured because for chemical exposure because of pollution, odd because of widen infection. It causes inflammation and inflammation least to to to fiber optic response."
• Indra Kumar Singh: "So what we think is like many flipping the balance of expression of these new these molecules in in in lung injury could be very helpful to control the 5 party given."

Technical Terms

• Pulmonary Fibrosis: A chronic and progressive lung disease characterized by the formation of scar tissue in the lungs.
• Fibroblasts: Cells that produce collagen and other components of the extracellular matrix.
• Myofibroblasts: Specialized fibroblasts that have contractile properties and play a key role in wound healing and fibrosis.
• Collagen: A fibrous protein that is a major component of connective tissue.
• Macrophages: Immune cells that engulf and digest cellular debris and pathogens.
• Preclinical Stage: The stage of research before clinical trials, involving laboratory and animal studies.
• Clinical Trials: Research studies that evaluate the safety and effectiveness of new medical treatments in humans.

Synthesis/Conclusion

Pulmonary fibrosis is a growing concern, particularly with an aging population and the long-term effects of COVID-19. While the condition is irreversible, research from Duke-NUS is exploring novel therapeutic strategies by targeting specific proteins involved in the fibrotic process. The potential repurposing of existing drugs that inhibit these proteins offers a promising avenue for future treatment options, although further research and clinical trials are necessary. Lifestyle modifications, such as avoiding smoking and maintaining a healthy lifestyle, can also play a role in mitigating the risk of developing pulmonary fibrosis.